作为一种新的治疗点,受体相互作用的血清/透蛋白激酶2作为一种新的治疗点
Morgane Rivoal1, Laurent Dubuquoy1, Régis Millet1
1Inserm, U1286 - INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000 Lille, France.
Journal of medicinal chemistry
|October 19, 2023
概括
受体相互作用的氨酸/氨酸蛋白激酶2 (RIPK2) 对于天生的免疫信号传递至关重要. 准RIPK2为炎症性疾病和癌症提供了潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 受体相互作用的氨酸/氨酸蛋白激酶2 (RIPK2) 是先天免疫的一个关键信号分子.
- 在病原体识别时,RIPK2调解NOD类受体 (NOD1和NOD2) 的激活.
- 这种激活会通过NF-κB和MAPK通路触发促炎细胞因子的释放.
研究的目的:
- 概述RIPK2的功能及其在疾病中的作用.
- 审查当前的RIPK2抑制剂和治疗策略.
- 讨论RIPK2向疗法的挑战和未来方向.
主要方法:
- 对RIPK2信号机制的文献综述.
- 对现有的RIPK2抑制剂和治疗方法的分析.
- 讨论疾病的相关性和未来研究前景.
主要成果:
- RIPK2对于NOD1/2-介导的先天性免疫反应至关重要.
- 失调的RIPK2信号与炎症性疾病和癌症有关.
- 目前正在研究针对RIPK2的各种抑制剂.
结论:
- RIPK2是细胞内信号传导的重要调解者.
- 准RIPK2为炎症和癌症提供了一个有前途的治疗途径.
- 需要进一步的研究来克服当前的挑战,并优化基于RIPK2的治疗方法.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
Enzyme-linked Receptors
78.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.6K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


